Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Osteogrow-C** is a personalized, locally implanted osteoinductive biologic-device combination developed by Genera Research for bone fracture nonunion. It contains recombinant human bone morphogenetic protein 6 in an autologous blood coagulum carrier, supplemented with tricalcium phosphate ceramics as a compression-resistant matrix. Locally delivered rhBMP6 activates bone morphogenetic protein receptor signaling to induce osteogenic differentiation and new bone formation, while the ceramic matrix provides mechanical support and osteoconductivity. The product is prepared intraoperatively from the patient's blood and implanted at the surgically stabilized fracture site. ([genera-research.com](https://genera-research.com/product/osteoforunion))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Osteogrow-C.